Brought to you by 
Start-up NovaCardia licenses renal compound from Kyowa Hakko
13 Aug 2007
Executive Summary
Diversified Japanese pharmaceutical company Kyowa Hakko licensed NovaCardia (developing cardiovascular and renal drugs) exclusive worldwide development and marketing rights outside of Asia to its adenosine A1 receptor antagonist (KW-3902) for regulating renal function.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Start-up NovaCardia licenses renal compound from Kyowa Hakko
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice